Intratympanic XXXX for intractable @entity9303 .

@entity1 @entity801 @entity9303 @entity16 @entity393 @entity394
OBJECTIVE: The study aimed to analyze the results of the intratympanic injection of @entity801 as a treatment option for @entity1 with unilateral @entity9303 who were refractory to medical treatment. STUDY DESIGN: Prospective study in the setting of a tertiary care medical center. METHODS: Seventy-one @entity1 with unilateral @entity9303 according to 1995 American Academy of Otolaryngology-Head and Neck Surgery 1995 guidelines who had been unresponsive to medical therapy for at least 1 year were studied. Intratympanic injections of a prepared concentration of 27 mg/mL @entity801 were performed at weekly intervals until the development of symptoms and signs indicative of @entity394 in the treated ear. As the main outcome measure, the 1995 American Academy of Otolaryngology-Head and Neck Surgery criteria for reporting treatment outcome in @entity9303 were used. The results of treatment were expressed in terms of control of vertigo, disability status (functional level and degree of overall impairment evaluated by the Dizziness Handicap Inventory and the University of California Los Angeles Dizziness Questionnaire), hearing level, and quantitative measurement of vestibular function. RESULTS: Vertigo was controlled in 83.1% of the 71 @entity1 . Recurrence of vertigo spells after initially complete control was noted in 17 @entity1 . In 13 of these @entity1 , this was cured by another course of intratympanic injections of @entity801 . Functional level and measures of self-reported handicap were significantly and promptly lowered after treatment in the @entity1 who attained control of vertigo. Hearing level as pure-tone average was unchanged 2 years after treatment, but @entity393 as a result of @entity801 injections occurred in 23 @entity1 at the end of treatment and in 9 and 11 @entity1 at 3 months and 2 years after the treatment, respectively. Vestibular function was kept normal or reduced in 49.3% of the @entity1 , whereas in the rest of the @entity1 vestibular areflexia was observed. Control of vertigo did not depend on the amount of @entity16 . CONCLUSIONS: Ending weekly intratympanic injections when clinical signs of vestibular deafferentation appear can control vertigo in the majority of @entity1 , and it is a useful alternative, together with other surgical options, for the treatment of @entity1 with @entity9303 who do not respond to medical treatment.
